1. fever within the past 96 hours of \>100.3 degrees fahrenheit 2. actively receiving therapy with an angiotensin-converting enzyme inhibitor (acei), angiotensin ii receptor blocker (arb), aliskiren, or sacubitril/valsartan 3. last known left ventricular ejection fraction of ≤40% 4. egfr \<30 ml/min/1.73m2 on screening labs, including patients on dialysis therapy 5. serum potassium \>5.0 meq/l on screening labs 6. prior intolerance, allergy or angioedema to acei, arb, or sacubitril/valsartan 7. pregnant or breast-feeding 8. in women of childbearing age, unwillingness to use birth control for the duration of the study 9. history of heart transplant or durable left ventricular assist device 10. currently implanted permanent pacemaker, defibrillator, or other device that would preclude cmr testing (cmr sub-study only) 11. currently participating in another trial of an investigational medication or device for covid-19. 12. any other condition that in the judgment of the investigator would jeopardize the patient's compliance with the study protocol

1. fever within the past 96 hours of \>100.3 degrees fahrenheit 2. actively receiving therapy with an angiotensin-converting enzyme inhibitor (acei), angiotensin ii receptor blocker (arb), aliskiren, or sacubitril/valsartan 3. last known left ventricular ejection fraction of ≤40% 4. egfr \<30 ml/min/1.73m2 on screening labs, including patients on dialysis therapy 5. serum potassium \>5.0 meq/l on screening labs 6. prior intolerance, allergy or angioedema to acei, arb, or sacubitril/valsartan 7. pregnant or breast-feeding 8. in women of childbearing age, unwillingness to use birth control for the duration of the study 9. history of heart transplant or durable left ventricular assist device 10. currently implanted permanent pacemaker, defibrillator, or other device that would preclude cmr testing (cmr sub-study only) 11. currently participating in another trial of an investigational medication or device for covid-19. 12. any other condition that in the judgment of the investigator would jeopardize the patient's compliance with the study protocol

fever within the past 96 hours of >100.3 degrees fahrenheit actively receiving therapy with an angiotensin-converting enzyme inhibitor (acei), angiotensin ii receptor blocker (arb), aliskiren, or sacubitril/valsartan last known left ventricular ejection fraction of ≤40% egfr <30 ml/min/1.73m2 on screening labs, including patients on dialysis therapy serum potassium >5.0 meq/l on screening labs prior intolerance, allergy or angioedema to acei, arb, or sacubitril/valsartan pregnant or breast-feeding in women of childbearing age, unwillingness to use birth control for the duration of the study history of heart transplant or durable left ventricular assist device currently implanted permanent pacemaker, defibrillator, or other device that would preclude cmr testing (cmr sub-study only) currently participating in another trial of an investigational medication or device for covid-19. any other condition that in the judgment of the investigator would jeopardize the patient's compliance with the study protocol

fever within the past 96 hours of >100.3 degrees fahrenheit actively receiving therapy with an angiotensin-converting enzyme inhibitor (acei), angiotensin ii receptor blocker (arb), aliskiren, or sacubitril/valsartan last known left ventricular ejection fraction of ≤40% egfr <30 ml/min/1.73m2 on screening labs, including patients on dialysis therapy serum potassium >5.0 meq/l on screening labs prior intolerance, allergy or angioedema to acei, arb, or sacubitril/valsartan pregnant or breast-feeding in women of childbearing age, unwillingness to use birth control for the duration of the study history of heart transplant or durable left ventricular assist device currently implanted permanent pacemaker, defibrillator, or other device that would preclude cmr testing (cmr sub-study only) currently participating in another trial of an investigational medication or device for covid-19. any other condition that in the judgment of the investigator would jeopardize the patient's compliance with the study protocol

1. fever within the past 96 hours of >100.3 degrees fahrenheit 2. actively receiving therapy with an angiotensin-converting enzyme inhibitor (acei), angiotensin ii receptor blocker (arb), aliskiren, or sacubitril/valsartan 3. last known left ventricular ejection fraction of ≤40% 4. egfr <30 ml/min/1.73m2 on screening labs, including patients on dialysis therapy 5. serum potassium >5.0 meq/l on screening labs 6. prior intolerance, allergy or angioedema to acei, arb, or sacubitril/valsartan 7. pregnant or breast-feeding 8. in women of childbearing age, unwillingness to use birth control for the duration of the study 9. history of heart transplant or durable left ventricular assist device 10. currently implanted permanent pacemaker, defibrillator, or other device that would preclude cmr testing (cmr sub-study only) 11. currently participating in another trial of an investigational medication or device for covid-19. 12. any other condition that in the judgment of the investigator would jeopardize the patient's compliance with the study protocol

1. fever within the past 96 hours of >100.3 degrees fahrenheit 2. actively receiving therapy with an angiotensin-converting enzyme inhibitor (acei), angiotensin ii receptor blocker (arb), aliskiren, or sacubitril/valsartan 3. last known left ventricular ejection fraction of ≤40% 4. egfr <30 ml/min/1.73m2 on screening labs, including patients on dialysis therapy 5. serum potassium >5.0 meq/l on screening labs 6. prior intolerance, allergy or angioedema to acei, arb, or sacubitril/valsartan 7. pregnant or breast-feeding 8. in women of childbearing age, unwillingness to use birth control for the duration of the study 9. history of heart transplant or durable left ventricular assist device 10. currently implanted permanent pacemaker, defibrillator, or other device that would preclude cmr testing (cmr sub-study only) 11. currently participating in another trial of an investigational medication or device for covid-19. 12. any other condition that in the judgment of the investigator would jeopardize the patient's compliance with the study protocol